Log on / register
Feedback | Support | My details
The evolving clinical profile of abatacept (CTLA4-Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis.
Ruderman EM, Pope RM
Arthritis Res Ther 2005, 7 Suppl 2:S21-5
[Full text] [PubMed] [Related articles] [Cited on BioMed Central]


printer friendly 
to  [Help]

BioMed Central articles that cite the above article:

1.
37%37%


 Review    
Recent developments in the immunobiology of rheumatoid arthritis
Andersson AK, Li C, Brennan FM
Arthritis Research & Therapy 2008, 10:204 (14 March 2008)
 [Abstract] [Full text] [PDF] [PubMed] [Related articles]
2.
37%37%


 Research article    
Arthritis suppression by NADPH activation operates through an interferon- pathway
Olofsson P, Nerstedt A, Hultqvist M, Nilsson EC, Andersson S, Bergelin A, Holmdahl R
BMC Biology 2007, 5:19 (9 May 2007)
 [Abstract] [Full text] [PDF] [PubMed] [Related articles]
3.
37%37%


 Review    
Modulating co-stimulation: a rational strategy in the treatment of rheumatoid arthritis?
Malmström V, Trollmo C, Klareskog L
Arthritis Research & Therapy 2005, 7(Suppl 2):S15-S20 (16 March 2005)
 [Full text] [PDF] [PubMed] [Related articles] [Cited on BioMed Central]
4.
37%37%


 Introduction    
The science of rheumatoid arthritis: a prelude
Smolen JS
Arthritis Research & Therapy 2005, 7(Suppl 2):S1-S3 (16 March 2005)
 [Full text] [PDF] [PubMed] [Related articles]

This article is also cited by a further 1 article in PubMed Central

printer friendly 
to  [Help]
Terms and Conditions Privacy statement Information for advertisers Jobs at BMC Contact us
© 1999-2009 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.